AMNEAL PHARMACEUTICALS, INC. (AMRX) Gross Margin
- Gross margin · 12 months: Value 39.32%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 39.32% | Gross profit / revenue. Period ending 2026-06-30. $1.23B ÷ $3.12B × 100 ≈ 39.32% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 1.23B USD | Gross Profit |
| Revenue | 3.12B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.89B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $1.23B | $3.12B | $1.89B | 39.32% |
| 2026-03-31 | $1.18B | $3.05B | $1.87B | 38.66% |
| 2025-12-31 | $1.11B | $3.02B | $1.91B | 36.88% |
| 2025-09-30 | $1.08B | $2.93B | $1.86B | 36.76% |
| 2025-06-30 | $1.07B | $2.85B | $1.78B | 37.67% |
| 2025-03-31 | $1.04B | $2.83B | $1.79B | 36.69% |
| 2024-12-31 | $1.02B | $2.79B | $1.77B | 36.52% |
| 2024-09-30 | $947.39M | $2.68B | $1.73B | 35.34% |
| 2024-06-30 | $910.37M | $2.60B | $1.69B | 35.04% |
| 2024-03-31 | $880.44M | $2.50B | $1.61B | 35.28% |
| 2023-12-31 | $820.57M | $2.39B | $1.57B | 34.28% |
| 2023-09-30 | $846.13M | $2.39B | $1.53B | 35.46% |
| 2023-06-30 | $807.83M | $2.31B | $1.49B | 34.94% |
| 2023-03-31 | $788.32M | $2.27B | $1.47B | 34.69% |
| 2022-12-31 | $784.71M | $2.21B | $1.42B | 35.47% |
| 2022-09-30 | $735.72M | $2.14B | $1.38B | 34.39% |
| 2022-06-30 | $740.00M | $2.12B | $1.35B | 34.87% |
| 2022-03-31 | $751.98M | $2.10B | $1.32B | 35.84% |
| 2021-12-31 | $768.97M | $2.09B | $1.30B | 36.73% |
| 2021-09-30 | $769.64M | $2.07B | $1.30B | 37.24% |
| 2021-06-30 | $704.72M | $2.06B | $1.32B | 34.25% |
| 2021-03-31 | $636.46M | $1.99B | $1.32B | 32.03% |
| 2020-12-31 | $628.39M | $1.99B | $1.33B | 31.54% |
| 2020-09-30 | $571.55M | $1.88B | $1.26B | 30.40% |
| 2020-06-30 | $492.40M | $1.74B | $1.17B | 28.32% |
| 2020-03-31 | $453.42M | $1.68B | $1.15B | 27.01% |
| 2019-12-31 | $353.00M | $1.63B | $1.15B | 21.70% |
| 2019-09-30 | $436.17M | $1.73B | $1.19B | 25.26% |
| 2019-06-30 | $581.84M | $1.82B | $1.19B | 31.89% |
| 2019-03-31 | $654.89M | $1.83B | $1.13B | 35.71% |
| 2018-12-31 | $716.40M | $1.66B | $946.59M | 43.08% |
| 2018-09-30 | (m) | $890.27M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | $597.46M | $1.02B | $420.77M | 58.68% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |